DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors

Zhang, Miaomiao; Wang, Yuanyuan; Chen, Xinzu; Zhang, Fan; Chen, Jiannan; Zhu, Hongqiao; Li, Jun; Chen, Zhengliang; Wang, Aying; Xiao, Yao; Chen, Zilu; Dong, Yanfang; Yin, Xuechen; Ji, Feng; Liu, Jie; Liang, Junqing; Pan, Feiyan; Guo, Zhigang; He, Lingfeng

doi:10.1007/s12094-023-03161-1

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, because dendritic cells (DCs) are responsible for antigen presentation and the promotion of T-cell infiltration, some researchers have recently tested the therapeutic effects of a DC vaccine combined with MSLN-CAR-T cells, and analyzed the infiltration of CAR-T cells using immunofluorescence. This showed that DC vaccines significantly enhanced the proliferation, infiltration, and persistence of the MSLN-CAR-T cells ( 89 ).…”

Section: Future Development Strategies For Car-t Cell Immunotherapymentioning

confidence: 99%

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Luo,

Zhang

2024

Front. Oncol.

View full text Add to dashboard Cite

Recent years have seen a marked increase in research on chimeric antigen receptor T (CAR-T) cells, with specific relevance to the treatment of hematological malignancies. Here, the structural principles, iterative processes, and target selection of CAR-T cells for therapeutic applications are described in detail, as well as the challenges faced in the treatment of solid tumors and hematological malignancies. These challenges include insufficient infiltration of cells, off-target effects, cytokine release syndrome, and tumor lysis syndrome. In addition, directions in the iterative development of CAR-T cell therapy are discussed, including modifications of CAR-T cell structures, improvements in specificity using multi-targets and novel targets, the use of Boolean logic gates to minimize off-target effects and control toxicity, and the adoption of additional protection mechanisms to improve the durability of CAR-T cell treatment. This review provides ideas and strategies for the development of CAR-T cell therapy through an in-depth exploration of the underlying mechanisms of action of CAR-T cells and their potential for innovative modification.

show abstract

Section: Future Development Strategies For Car-t Cell Immunotherapymentioning

confidence: 99%

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Luo,

Zhang

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges

Wang,

Liu,

Hao

et al. 2024

Infectious Diseases &Amp; Immunity

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR-T) cell therapy, renowned for its successes in cancer treatment, is now entering the field of human immunodeficiency virus (HIV) therapy, presenting both opportunities and challenges. With the emergence of broadly neutralizing antibodies, multi-target CARs, and T cell receptor–like antibodies aimed at increasing specificity in targeting HIV reservoirs, CAR-T therapy is synergizing with other cutting-edge treatments, including gene-editing technologies, therapeutic vaccines, and latency-reversing agents, in pursuit of a potential functional cure. In this review, we delve into the role of CAR-T therapy in HIV treatment, highlighting its potential to overcome clinical obstacles. We discuss advancements in targeting strategies within CAR constructs and the intricate regulation of T cell proliferation and chemotaxis. Moreover, we explore the use of diverse immune cells, such as gamma-delta T cells and natural killer cells. We review advanced biotechnologies, manufacturing innovations, viral mechanisms, and immune microenvironments. We also discuss the current research landscape and potential future applications of CAR-T therapy against HIV, which remains a critical global health challenge.

show abstract

DC vaccine enhances CAR-T cell antitumor activity by overcoming T cell exhaustion and promoting T cell infiltration in solid tumors

Cited by 2 publications

References 44 publications

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges

Contact Info

Product

Resources

About